| Revision as of 14:18, 5 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,074 edits Saving copy of the {{drugbox}} taken from revid 458440242 of page Pritumumab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 03:38, 3 December 2023 edit Citation bot (talk | contribs)Bots5,456,920 edits Add: doi-access. | Use this bot. Report bugs. | #UCB_CommandLine |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 458439163 |
|
| verifiedrevid = 464214576 |
|
| image = |
|
| image = |
|
|
|
|
<!--Monoclonal antibody data--> |
|
<!-- Monoclonal antibody data --> |
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = u |
|
| source = u |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
|
| tradename = |
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| pregnancy_AU = |
|
| pregnancy_AU = |
|
| pregnancy_US = |
|
| pregnancy_US = |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = |
|
| legal_AU = |
|
| legal_CA = |
|
| legal_CA = |
|
| legal_UK = |
|
| legal_UK = |
|
| legal_US = |
|
| legal_US = |
|
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
| legal_status = |
|
|
⚫ |
<!-- Pharmacokinetic data --> |
| ⚫ |
| routes_of_administration = |
|
|
|
| bioavailability = |
|
|
|
|
⚫ |
| protein_bound = |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = |
| ⚫ |
| protein_bound = |
|
|
| metabolism = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| excretion = |
|
|
⚫ |
| ChemSpiderID = none |
|
|
|
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ⚫ |
| ChemSpiderID = NA |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = <!-- blanked - oldvalue: 499212-74-7 --> |
|
| CAS_number = 499212-74-7 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = Z6Q90D1G53 |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| C=6440 | H=9968 | N=1708 | O=2016 | S=42 |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| C=6440 | H=9968 | N=1708 | O=2016 | S=42 |
|
|
| molecular_weight = 150 ] |
|
|
}} |
|
}} |
|
|
|
|
|
'''Pritumumab''' ('''PTB''') is a ] ] targeted against ].<ref name="Babic_2018">{{cite journal | vauthors = Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S | title = Pritumumab, the first therapeutic antibody for glioma patients | journal = Human Antibodies | volume = 26 | issue = 2 | pages = 95–101 | date = February 2018 | pmid = 29036806 | doi = 10.3233/HAB-170326 | s2cid = 3266191 }}</ref> It works by binding to the ecto-domain of ] on the surface of cancer cells.<ref name="Babic_2018" /><ref>{{cite journal | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | archive-url = https://web.archive.org/web/20120211194153/https://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | archive-date = 11 February 2012 | journal = WHO Drug Information | volume = 18 | issue = 1 | date = 2004 }}</ref> developed by ]. |
|
|
|
|
|
It is in clinical trials for the treatment of ].<ref>{{cite web | url = http://www.nascentbiologics.com/news/science/70-proven-cancer-cure-back-in-the-hands-of-us-inventor-after-27-years-in-japan | title = Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan | date = 1 October 2009 | publisher = Nascent Biologics | archive-url = https://web.archive.org/web/20110714154240/http://www.nascentbiologics.com/news/science/70-proven-cancer-cure-back-in-the-hands-of-us-inventor-after-27-years-in-japan | archive-date = 2011-07-14 }}</ref><ref>{{ClinicalTrialsGov|NCT04396717|Safety Study of Pritumumab in Brain Cancer}}</ref> The ] granted ] designation in 2015. |
|
|
|
|
|
The target of '''Pritumumab''', cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV).<ref name="pmid26801988">{{cite journal | vauthors = Yu YT, Chien SC, Chen IY, Lai CT, Tsay YG, Chang SC, Chang MF | title = Surface vimentin is critical for the cell entry of SARS-CoV | journal = Journal of Biomedical Science | volume = 23 | pages = 14 | date = January 2016 | pmid = 26801988 | pmc = 4724099 | doi = 10.1186/s12929-016-0234-7 | doi-access = free }}</ref> |
|
|
|
|
|
PTB has been proposed as a potential treatment for COVID-19 and related Viral Infections.<ref>{{cite web | title = Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens | date = 17 June 2020 | work = Financialnewsmedia.com | url = https://www.prnewswire.com/news-releases/race-for-vaccine-intensifies-as-covid-19-second-wave-of-outbreaks-threatens-301078296.html }}</ref> |
|
|
|
|
|
==References== |
|
|
{{reflist}} |
|
|
|
|
|
{{Monoclonals for tumors}} |
|
|
|
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |